Question to the Department of Health and Social Care:

To ask His Majesty's Government how many of the commercial engagements made by NHS England between June 2021 and July 2026 involving indication-specific pricing were for indications for (1) kidney conditions, and (2) rare kidney conditions.

NHS England has not entered into any commercial agreements involving indication-specific pricing for kidney conditions, or for rare kidney conditions, between June 2021 and July 2026. However, during this period, NHS England has entered into three commercial agreements involving indication-specific pricing for kidney cancer indications, including renal cell carcinoma indications.

NHS England regularly engages with patient groups, including the Charity Medicines Access Coalition, Genetic Alliance UK, and the Neurological Alliance, whose members represent people living with a wide range of rare conditions. More recent engagement has included patient groups representing people with conditions such as spinal muscular atrophy, muscular dystrophy, and motor neurone disease, where National Institute for Health and Care Excellence technology appraisals have been undertaken or are ongoing.

As part of the upcoming consultation on updates to the NHS Commercial Framework for New Medicines, NHS England will seek views from a broad range of patient organisations, including those representing people with rare diseases.